The user experienced significant hair shedding after long-term use of finasteride and dutasteride and is now considering trying RU58841 as a last resort. They have checked health factors and suspect stress and poor sleep may contribute to the shedding, but they are determined to try RU58841 to see if it helps with androgenetic alopecia.
A user shared their experience using RU58841, Minoxidil, and Finasteride for hair loss, noting good results but increased acne from RU58841. They plan to replace RU58841 with Finasteride while continuing Minoxidil.
The user discusses using Minoxidil for hair loss and is considering RU58841 to reduce excessive oil production. They seek advice on RU58841's effectiveness in blocking sebum production.
RU58841 may still be potent after being left unopened for four months if protected from light and air. A user reported hair improvement using RU58841 with minoxidil, without major shedding, over 2.5 years.
Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.
Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.
The user experienced side effects from finasteride and is considering switching to dutasteride, while also using pyrilutamide to protect hair follicles. They are seeking advice on whether to add RU58841 to their regimen.
The conversation discusses the duration of hair shedding caused by RU58841. The user is stressed and seeking information on how long the shedding phase lasts.
A user is considering quitting RU58841 after using it for over three years alongside Dutasteride and Oral Minoxidil, and is concerned about potential hair loss. Other users share mixed opinions on RU58841's effectiveness, with some suggesting continued use of other treatments like Dutasteride and Minoxidil.
The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
A user is combining RU58841 with a topical formula containing finasteride, dutasteride, minoxidil, triamcinolone, caffeine, and other ingredients. They have just started using it and report no side effects so far.
Matt-3422 shared his hair loss treatment journey, starting with great results from Minoxidil and oral Finasteride, then switching to RU58841 and topical Finasteride due to worsening hair loss. He's experiencing scalp irritation and is unsure if he should continue with his current regimen, while others suggest scalp care and alternative treatments.
RU58841 is generally considered ineffective as a standalone hair loss treatment, with most users combining it with finasteride or dutasteride for better results. Few report success using RU58841 alone.
A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.
The user plans to use RU58841 in the morning and Pyrilutamide in the evening for hair loss treatment, considering replacing Fluridil with Pyrilutamide. They believe Pyrilutamide is effective.
Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.
User TopBack56 and friends tried pyrilutamide (KX-826) for hair loss without experiencing negative side effects. They observed fine vellus hairs but no thick hair growth yet, and plan to add GT20029 to their regime after safety trials.
Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.
The user is experiencing a greasy and dandruff-prone scalp from using RU58841 with glycerin and is seeking alternative carriers for seborrheic dermatitis. They are also using dutasteride 0.5mg.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
A user shared progress pictures 1.5 months after a hair transplant of 3500 grafts, using oral finasteride, topical finasteride, minoxidil, and vitamins. They are concerned about potential shock loss and the thinning appearance.
The conversation is about the availability of the research chemical GT20029 for hair loss treatment and when companies like Anageninc will have it. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
The conversation is about using RU58841 for hair loss after finasteride didn't work, with the user considering trying RU before minoxidil. Another user suggests trying oral dutasteride and oral minoxidil first.
RU58841 is used for hair loss, with mixed effectiveness and potential side effects like heart issues. Some users find it effective, while others see no results; alternatives like finasteride and dutasteride are also mentioned.
A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair follicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.
RU58841 users discuss increasing dosage for better hair regrowth, with some considering adding minoxidil and finasteride. Users report mixed results, with some experiencing side effects at higher doses.
Koshine 826 (Pyrilutamide) has mixed reviews, with some users experiencing side effects like insomnia and others seeing minimal results. Concerns about the company's transparency and lack of progress photos are noted.